Serum prostate specific antigen and prostate specific antigen density in patients receiving radical prostatectomy.
OBJECTIVE
To study the significance of prostate specific antigen (PSA) and prostate specific antigen density (PSAD) for predicting the risk of occult metastatic disease and extra-prostatic invasion of prostate cancer in patients receiving radical prostatectomy.


METHODS
The cases of 41 consecutive patients who underwent radical prostatectomy were reviewed. Relations of PSA and PSAD using Markit M PATM assay for grade, preoperative clinical stage, postoperative pathological stage, capsular penetration, seminal vesicle invasion, resection margins and lymph node metastasis are discussed.


RESULTS
Although serum PSA was correlated with PSAD and PSA was correlated with preoperative prostate volume, PSAD was not influenced by prostate volume. PSA correlated only with the grade, while PSAD was correlated with grade, preoperative clinical stage, postoperative pathological stage, capsular penetration, seminal vesicle invasion, resection margins and lymph node metastasis. In addition, sixty-two percent (8/13) of margin positive patients showed a PSAD value of more than 0.4, while 93% (26/28) of margin negative patients showed less than 0.4. Sixty-seven percent (6/9) of lymph node positive patients showed a PSAD of more than 0.4, while 91% (29/32) of lymph node negative patients showed less than 0.4.


CONCLUSIONS
We concluded that PSAD was useful for predicting extra-prostatic involvement of prostatic cancer.
Masai
M
M
Department of Urology, Teikyo University, Ichihara Hospital, Japan.
Ito
H
H
Kotake
T
T
Nagao
K
K
D000230:Adenocarcinoma / Q000097:blood* / Q000473:pathology*; D000368:Aged; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology*; D012189:Retrospective Studies; D012306:Risk
D017430:Prostate-Specific Antigen